and society,12 and effective strategies are urgently needed to help the public, clinicians, and policy makers address this problem. Communication about overdiagnosis has been highlighted as essential for moving forward but presents several challenges, such as the potential to confuse the public, undermine trust, and adversely affect people who already have a diagnosis. Various 
Box 11 Overdiagnosis andits consequences12
Overdiagnosis occurs when a diagnosis is "correct" according to current professional standards but when the diagnosis or associated treatment has a low probability ofbenefitingthepersondiagnosed.2 Itis caused by a range of factors such as:
• Use of increasinglysensitive tests that identify abnormalities that are indolent, non-progressive, or regressive (overdetection)
• Expanded definitions ofdisease-for example, by formal advisory bodies consisting of experienced practitioners, public health officials, vaccinologists, and epidemiologists. Available data are reviewed, burden of disease assessed, and practical considerations for vaccine delivery evaluated to produce an appropriate schedule for each country. So, expert advisory bodies may develop differing recommended schedules, based on local, regional, or national considerations. For example, the second dose of MMRvaccine is routinely given in Germany at 15-23 months of age, while in the US it is administered at 4 to 6 years. Strong trial generated evidence shows that two doses separated by at least 28 days and the first dose administered on or after the first birthday will produce measles immunity in 99% or more of people. The timing of the second dose varies in each country is based on the ability to provide the earliest possible second dose that will minimise the burden of measles. Ongoing surveillance of measles cases ensures that the timing of doses remains appropriate to the epidemiology of disease.
Monitoring optimises protection
Evidence continues to be gathered and used after implementation. The increase in Haemophilusinfluenzae type b (Hib) cases in the United Kingdom after implementation of a Hib conjugate vaccine schedule at 2, 3, and 4 months prompted an altered schedule that moved the 3 month dose to 12-13 months, with a resultant reduction in the burden of Hib disease.10 The value of continued surveillance was also highlighted by the introduction of maternal tetanus, diphtheria, and acellular pertussis (Tdap) vaccination to reduce pertussis among infants in the US and many European countries.11
In summary, vaccine schedules are evidence based, safe, and highly effective in reducing the global burden of infectious diseases. Evidence to develop and maintain these schedules involves a multifactorial and robust process carried out worldwide. The real world effectiveness is shown by the millions of children spared annually from the morbidity and mortality of vaccine preventable infections. 
